Abstract Library

#3515 PRESTO 2: An international patient survey to evaluate impact of injection and delivery system on local pain when administering somatostatin analogue (SSA) therapy

Introduction: Long-acting (LA) SSA therapy is a common long-term treatment for NETs, but real-world data on patients’ injection experience using the latest LA SSA designs/formulations are limited.

Conference:

Presenting Author: O'Toole D

Authors: O'Toole D, Prebtani A, Webb S, Houchard A, Gueguen D,

Keywords: acromegaly, injection site pain, lanreotide autogel/depot, neuroendocrine tumor, octreotide long-acting release syringe, patient survey,

#3182 Cost of carcinoid syndrome (CS) In France: Analysis of the national health insurance database

Introduction: CS develops in approximately 20% of patients with neuroendocrine tumors (NET). The cost of its management has never been studied in France.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Walter T

Authors: Perrier M, Mouawad C, Gueguen D, Bouille C, Laborey M,

Keywords: carcinoid syndrome, resources, healthcare expenditure,

#3041 Resource Use in Patients with Carcinoid Syndrome: A Retrospective Analysis Using the French Health Insurance National (SNDS) Database

Introduction: About 20% of patients (pts) with neuroendocrine tumors (NET) suffer from carcinoid syndrome (CS), mainly from ileum and lung NET. Pts with CS experience symptoms such as diarrhea, flushes and cardiac complications. The diarrhea occurs in almost all pts with CS and can be truly debilitating. Therefore, on top of the tumor, the burden of the symptoms further impairs quality of life and is associated with additional costs related to symptom management and pts follow-up.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Walter T

Authors: Walter T, Lapeyre Mestre M, Gueguen D, Bouille C, Laborey M,

Keywords: Carcinoid syndrome, resources, health economics,

#2824 Patient and Nurse Satisfaction with the New Lanreotide Autogel Pre-Filled Syringe in Neuroendocrine Tumors (NET): A Prospective Study (SONATE)

Introduction: A new syringe (NS) for the delivery of lanreotide autogel was approved in Oct 2018 in France. The NS includes updated features (larger flanges, more robust plunger) intended to ease the injection.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Walter T, Eskenazi M, Rama N, Gueguen D, Mir O,

Keywords: neuroendocrine tumors, lanreotide, nursing, patient-reported outcomes,

#2263 Patient Survey Devoted to Characterizing Experience and Expectations of Patients with Neuroendocrine Tumors (NET)

Introduction: Patients (pts) with NET experience consequences of disease progression and treatments; their preferences can influence the choice and success of therapeutic strategies.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: SARABI M

Authors: Sarabi M, Gueguen D, Walter T, Hentic O, Baudin E,

Keywords: Patient Report Outcomes, Neuroendocrine Tumor, Quality of life,